Current Report Filing (8-k)
May 04 2017 - 3:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 4, 2017
Zafgen, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-36510
|
|
20-3857670
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
175 Portland Street, 4th Floor
Boston, Massachusetts
|
|
02114
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code
(617) 622-4003
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this
chapter).
Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 4, 2017, Zafgen, Inc. (the Company) announced that it ended the first quarter of 2017 with $116.9 million in cash,
cash equivalents and marketable securities and remains on track to end 2017 with greater than $65 million in cash, cash equivalents and marketable securities. The Company expects to announce its full financial results for the first quarter of
2017 next week.
The information in this Item 2.02 is intended to be furnished and shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended (the Securities Act), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 7.01 Other Events
On
May 4, 2017, the Company issued a press release announcing the results of its Phase 1 clinical trial of
ZGN-1061,
its second generation MetAP2 inhibitor. A copy of the press release is furnished as
Exhibit 99.1 hereto.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act,
except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release issued by Zafgen, Inc. on May 4, 2017, furnished herewith.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: May 4, 2017
|
|
|
|
ZAFGEN, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Thomas E. Hughes
|
|
|
|
|
|
|
Thomas E. Hughes, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release issued by Zafgen, Inc. on May 4, 2017, furnished herewith.
|
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Apr 2024 to May 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Zafgen Inc (NASDAQ): 0 recent articles
More Zafgen, Inc. News Articles